Immunoliposomes containing antibodies to costimulatory molecules as adjuvants for HIV subunit vaccines

AIDS Research and Human Retroviruses

Volumn 14, Issue 5, 1998, Pages 409-417

  Ozpolat, Bulent ^a   Rao, Xiao Mei ^a   Powell, Michael F ^b   Lachman, Lawrence B ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIBODY; CD28 ANTIGEN; CTLA 4 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLYCOPROTEIN GP 120; IMMUNOLIPOSOME; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOSTIMULATION; INTERFERON PRODUCTION; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032549557     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.409     Document Type: Article

References (37)

1. Bluestone JA: New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995;2:555-559.
2. Thompson CB: Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 1995;81:979-982.
3. Allison JP: CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994;6:414-419.
4. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, and Tepper MA: Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992;257:792-795.
5. Gimmi CD, Freeman GJ, Gribben JG, Gray G, and Nadler LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993;90: 6586-6590.
6. Seder RA and Paul WE: Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994;12:635-673.
7. Powrie F and Coffman RL: Cytokine regulation of T-cell function: Potential for therapeutic intervention. Immunol Today 1993;14: 270-274.
8. Mosmann TR: T lymphocyte subsets, cytokines, and effector functions. Ann NY Acad Sci 1992;664:89-92.
9. Linsley PS, Clark EA, and Ledbetter JA: T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990;87:5031-5035.
10. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, and Somoza C: B70 antigen is a second ligand for CTLA-4 and CD28. Nature (London) 1993;366:76-79.
11. Razi-Wolf Z, Falo LD, Jr, and Reiser H: Expression and function of the costimulatory molecule B7 on murine Langerhans cells: Evidence for an alternative CTLA-4 ligand. Eur J Immunol 1994;24: 805-811.
12. Reiser H, Freeman GJ, Razi Wolf Z, Gimmi CD, Benacerraf B, and Nadler LM: Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci USA 1992;89: 271-275.
13. Murphy EE, Terres G, Macatonia SE, Hsieh CS, Mattson J, Lanier L, Wysocka M, Trinchieri G, Murphy K, and O'Garra A: B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 1994;180:223-231.
14. Townsend SE and Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-370.
15. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, and Nadler LM: B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 1991;88:6575-6579.
16. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, and Damle NK: Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992;176:1595-1604.
17. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, and Bluestone JA: CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-413.
18. Krummel MF and Allison JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-465.
19. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, and Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985-988.
20. Wu Y, Guo Y, Huang A, Zheng P, Liu Y: CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion. J Exp Med 1997;185:1327-1335.
21. Leach DR, Krummel MF, and Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1735.
22. Gregoriadis G, Davis D, and Davies A: Liposomes as immunological adjuvants: Antigen incorporation studies. Vaccine 1987;5: 145-151.
23. Phillips NC, Gagne L, Tsoukas C, and Dahman J: Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status. J Immunol 1994;152:3168-3174.
24. Lachman LB, Shih L-CN, Rao X-M, Hu X, Bucana CD, Ullrich SE, and Cleland JL: Cytokine-containing liposomes as adjuvants for HIV subunit vaccines. AIDS Res Hum Retroviruses 1995;11: 921-932.
25. Ullrich SE and Fidler IJ: Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens. J Leukocyte Biol 1992;52:489-494.
26. Springer TA, Davignon D, Ho MK, Kurzinger K, Martz E, and Sanchez M: LFA-1 and Lyt-2,3, molecules associated with T lymphocyte-mediated killing; and Mac-1, an LFA-1 homologue associated with complement receptor function. Immunol Rev 1982;68: 171-195.
27. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, and Glimcher LH: B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: Application to autoimmune disease therapy. Cell 1995;80:707-718.
28. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, and Bluestone JA: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789-792.
29. Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei RQ, Gibson ML, Zheng XG, Myrdal S, Gordon D, et al.: T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89:11102-11105.
30. Finck BK, Linsley PS, and Wofsy D: Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-1227.
31. Phillips NC and Dahman J: Immunogenicity of immunoliposomes: Reactivity against species-specific IgG and liposomal phospholipids. Immunol Lett 1995;45:149-152.
32. Carmichael A, Jin X, Sissons P, and Borysiewicz L: Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993;177:249-256.
33. Rinaldo C, Huang XL, Fan ZF, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, and Cottrill M: High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995;69:5838-5842.
34. Klein MR, Van BC, Holwerda AM, Kerkhof GS, Bende RJ, Keet IP, Eeftinck-Schattenkerk JK, Osterhaus AD, Schuitemaker H, and Miedema F: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-1372.
35. Doe B, Steimer KS, and Walker CM: Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans. Eur J Immunol 1994;24:2369-2376.
36. Casement KS, Nehete PN, Arlinghaus RB, and Sastry KJ: Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1. Virology 1995;211:261-267.
37. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, and Bluestone JA: CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-413.